Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Recruiting

• Conditions: Non Small Cell Lung Cancer

• Registration Number: NCT05669105
• Lead Sponsor: Sanguine Biosciences

Brief Summary

The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-19
• Study First Submitted: 2022-12-13
• Study First Submitted QC: 2022-12-28
• Study First Posted: 2022-12-30
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-20
• Last Update Posted: 2023-11-22
• Primary Completion: 2024-03-31
• Study Completion: 2024-03-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Participants willing and able to provide written informed consent
• Participants are willing and able to provide appropriate photo identification
• Participant's age 18 - 100 years old
• Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.)
• Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records

Exclusion Criteria

• Participants who are pregnant or nursing
• Participants with a known history of HIV, hepatitis, or other infectious diseases
• Participants who have taken an investigational product in the last 30 days
• Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months
• Participants currently enrolled in a clinical trial
• Participants currently in remission

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biospecimen & Clinical Data Collection	10 years	The primary objective is to collect 2000 whole blood samples from subjects who are diagnosed with active lung cancer.; The purpose of this study is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations can analyze how the immune response can take place, and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options.

Trial Locations

Locations (1)

Sanguine Biosciences; 🇺🇸 Waltham, Massachusetts, United States